"There are more than 700 million cases of otitis media every year, with 30 million children suffering from chronic infections annually. As a result, otitis media is one of the major drivers of community antibiotic usage,” Dr Neville said.
“Unfortunately, this increased usage ultimately leads to higher rates of antibiotic resistance, making middle ear infections much harder to treat.”
With these huge numbers only in one of several common problems, which PBT2 can most likely treat, it is sure that PBT2 has a huge value. It is owned by ATH.
Looks like some potential investors are in a coma as was suggested by SunnyKabs. IMO,
PBT2 for Middle Ear Infections, page-4
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $2.401K | 800.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 110142186 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 150940914 | 62 |
View Market Depth
| Last trade - 10.20am 08/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |